Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation

Catheterization and Cardiovascular Interventions

Volumn 80, Issue 3, 2012, Pages 395-405

  Musumeci, Giuseppe ^a   Rossini, Roberta ^a   Lettieri, Corrado ^b   Capodanno, Davide ^c   Romano, Michele ^b   Rosiello, Renato ^b   Guagliumi, Giulio ^a   Valsecchi, Orazio ^a   Gavazzi, Antonello ^a   Angiolillo, Dominick J ^d  

^a OSPEDALI RIUNITI   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

antiplatelets; bleeding; clopidogrel; drug eluting stents; stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ANEMIA; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DEATH; DRUG ELUTING STENT; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENDER; HEART DEATH; HEART INFARCTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREVALENCE; PROGNOSIS; RISK FACTOR; STENT THROMBOSIS;

AGED; ASPIRIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; ITALY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; PROSTHESIS DESIGN; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865623257     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.23337     Document Type: Article

References (42)

1. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001; 358: 527-533. (Pubitemid 32772726)
3. Steinhubl SR, Berger PB, Mann JT III, Fry ET, DeLago A, Wilmer C, Topol EJ,. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. J Am Med Assoc 2002; 288: 2411-2420. (Pubitemid 35340537)
4. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. J Am Med Assoc 2007; 297: 159-168. (Pubitemid 46089732)
5. Stabile E, Cheneau E, Kinnaird T, et al. Late thrombosis in cypher stents after the discontinuation of antiplatelet therapy. Cardiovasc Radiat Med 2004; 5: 173-176. (Pubitemid 44556561)
6. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006; 113: 2803-2809. (Pubitemid 44305292)
7. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521. (Pubitemid 39410418)
8. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130. (Pubitemid 40617065)
9. Rossini R, Capodanno D, Lettieri C, et al. Prevalence, predictors, and long-term prognosis of premature discontinuation of oral antiplatelet therapy after drug eluting stent implantation. Am J Cardiol 2011; 107: 186-194.
10. Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med 2010; 362: 1374-1382.
11. Kandzari DE, Angiolillo DJ, Price MJ, Teirstein PS,. Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. J Am Coll Cardiol Cardiovasc Interv 2009; 2: 1279-1285.
12. Airoldi F, Colombo A, Morici N, et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007; 116: 745-754. (Pubitemid 47255992)
13. Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J 2009; 30: 2714-2721.
14. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007; 49: 1982-1988. (Pubitemid 46694290)
15. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337.
16. Tsai TT, Ho PM, Xu S, et al. Increased risk of bleeding in patients on clopidogrel therapy after drug-eluting stents implantation: Insights from the HMO Research Network-Stent Registry (HMORN-stent). Circ Cardiovasc Interv 2010; 3: 230-235.
17. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, Topol EJ, Manoukian SV,. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial. Am J Cardiol 2007; 100: 1364-1369. (Pubitemid 47576015)
18. Moscucci M, Fox KA, Cannon CP, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815-1823. (Pubitemid 37280247)
19. Mehran R, Pocock SJ, Stone GW, et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: A risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457-1466.
20. Mehran R, Pocock SJ, Nikolsky E, et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55: 2556-2566.
21. Grines CL, Bonow RO, Casey DE Jr, et al. American Heart Association; American College of Cardiology; Society for Cardiovascular Angiography and Interventions; American College of Surgeons; American Dental Association; American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007; 115: 813-818. (Pubitemid 46294748)
22. Rao AK, Pratt C, Berke A, et al. Thrombolysis In Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988; 11: 1-11. (Pubitemid 18029027)
23. World Health Organization. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968; 405: 5-37.
24. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE,. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029. (Pubitemid 46376802)
25. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015. (Pubitemid 350106708)
26. Haas S,. Rivaroxaban-An oral, direct Factor Xa inhibitor: Lessons from a broad clinical study program. Eur J Haematol 2009; 82: 339-349.
27. Latib A, Morici N, Cosgrave J, Airoldi F, Godino C, Brambilla N, Chieffo A, Bonizzoni E, Carlino M, Bedogni F, Montorfano M, Sangiorgi GM, Briguori C, Colombo A,. Incidence of bleeding and compliance on prolonged dual antiplatelet therapy (aspirin + thienopyridine) following drug-eluting stent implantation. Am J Cardiol 2008; 102: 1477-1481.
28. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S,. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774-882.
29. Manoukian SV, Feit F, Mehran R, et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: An analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49: 1362-1368. (Pubitemid 46476844)
30. Alexander KP, Chen AY, Roe MT, et al. CRUSADE Investigators. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005; 294: 3108-3116. (Pubitemid 43016802)
31. Ko DT, Yun L, Wijeysundera HC, et al. Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years. Circ Cardiovasc Interv 2010; 3: 140-147.
32. Maroko PR, Braunwald E,. Effects of metabolic and pharmacologic interventions on myocardial infarct size following coronary occlusion. Circulation 1976; 53 (Suppl 3): I162-I168.
33. Levy PS, Kim SJ, Eckel PK, et al. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol 1993; 265: H340-H349. (Pubitemid 23224729)
34. Levy PS, Quigley RL, Gould SA,. Acute dilutional anemia and critical left anterior descending coronary artery stenosis impairs end organ oxygen delivery. J Trauma 1996; 41: 416-423. (Pubitemid 26318068)
35. Riva E, Tettamanti M, Mosconi P, et al. Association of mild anemia with hospitalization and mortality in the elderly: The Health and Anemia population-based study. Haematologica 2009; 94: 22-28.
36. Ezekowitz JA, McAlister FA, Armstrong PW,. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003; 107: 223-225. (Pubitemid 36135214)
37. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, Berger PB,. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119. (Pubitemid 34267412)
38. Tsujita K, Nikolsky E, Lansky AJ, et al. Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial). Am J Cardiol 2010; 105: 1385-1394.
39. Gottlieb SS, McCarter RJ, Vogel RA,. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489-497. (Pubitemid 28384881)
40. Bhatt DL, Roe MT, Peterson ED, et al. CRUSADE Investigators. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA 2004; 292: 2096-2104. (Pubitemid 39435100)
41. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-935. (Pubitemid 37214804)
42. Kim YH, Lee JY, Ahn JM, et al. Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. JACC Cardiovasc Interv 2011; 4: 423-431.